Neuronetics will release Q3 2025 financial results on November 4, 2025, followed by a conference call at 8:30 a.m. ET.
Quiver AI Summary
Neuronetics, Inc., a medical technology company specializing in neurohealth products, announced it will release its third quarter 2025 financial and operational results on November 4, 2025, before the market opens, followed by a conference call at 8:30 a.m. Eastern Time. The call will be available via a live webcast. Neuronetics is known for its NeuroStar® Advanced Therapy, a leading non-invasive treatment for mental health disorders, particularly major depressive disorder (MDD). The company operates Greenbrook TMS centers in the U.S., offering NeuroStar Therapy and SPRAVATO® (esketamine) for treatment-resistant depression. NeuroStar has delivered over 7.6 million treatments and holds the largest clinical data set for TMS therapy, underlining its commitment to providing effective mental health solutions. For further details, interested parties can visit their website or reach out to their investor and media contacts.
Potential Positives
- Neuronetics plans to release its third quarter 2025 financial and operating results on November 4, 2025, signaling transparency and engagement with investors.
- The upcoming conference call will provide an opportunity for stakeholders to gain insights into the company's performance and strategic direction.
- Neuronetics emphasizes its leadership in TMS therapy for major depressive disorder (MDD), having delivered over 7.6 million treatments, which indicates strong market presence and experience.
- The company operates Greenbrook TMS treatment centers, contributing to its revenue stream and expanding access to non-drug treatments for mental health disorders.
Potential Negatives
- The press release does not provide any insights or forecasts about the company's financial performance for the upcoming quarter, which may raise questions among investors about its growth trajectory and financial health.
- The timing of the financial results announcement leaves a gap between now and November 4, potentially allowing market speculation which could affect stock performance.
FAQ
When will Neuronetics announce its third quarter 2025 financial results?
Neuronetics will release its third quarter 2025 financial results on November 4, 2025, prior to market open.
How can I participate in the Neuronetics conference call?
You can join the conference call by registering via the provided link, and it will start at 8:30 a.m. ET on November 4.
Where can I listen to the Neuronetics conference call?
The conference call will be available via live webcast at https://edge.media-server.com/mmc/p/yxrs8osc.
What is NeuroStar Advanced Therapy?
NeuroStar Advanced Therapy is a non-drug, noninvasive TMS treatment for mental health conditions, especially major depressive disorder.
How many treatments has NeuroStar Advanced Therapy provided?
NeuroStar Advanced Therapy has delivered over 7.6 million treatments, supported by extensive clinical data.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STIM Insider Trading Activity
$STIM insiders have traded $STIM stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $STIM stock by insiders over the last 6 months:
- ASSET MANAGEMENT, LP MADRYN has made 0 purchases and 3 sales selling 3,500,000 shares for an estimated $13,020,000.
- STEPHEN FURLONG (EVP, CFO and Treasurer) has made 0 purchases and 2 sales selling 200,000 shares for an estimated $853,280.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STIM Hedge Fund Activity
We have seen 47 institutional investors add shares of $STIM stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 1,823,354 shares (+438.4%) to their portfolio in Q2 2025, for an estimated $6,363,505
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 663,569 shares (-87.1%) from their portfolio in Q2 2025, for an estimated $2,315,855
- MORGAN STANLEY added 574,770 shares (+806.5%) to their portfolio in Q2 2025, for an estimated $2,005,947
- GEODE CAPITAL MANAGEMENT, LLC added 556,268 shares (+172.3%) to their portfolio in Q2 2025, for an estimated $1,941,375
- VANGUARD GROUP INC added 436,544 shares (+18.9%) to their portfolio in Q2 2025, for an estimated $1,523,538
- GHISALLO CAPITAL MANAGEMENT LLC removed 400,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,396,000
- STATE STREET CORP added 308,287 shares (+257.8%) to their portfolio in Q2 2025, for an estimated $1,075,921
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MALVERN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS), announced that it plans to release third quarter 2025 financial and operating results prior to market open on Tuesday, November 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
The conference call will be broadcast live in listen-only mode via webcast at
https://edge.media-server.com/mmc/p/yxrs8osc
. To listen to the conference call on your telephone, participants may register for the call
here
. While it is not required, it is recommended you join 10 minutes prior to the event start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.6 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com .
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
[email protected]
Media Contact:
EvolveMKD
646-517-4220
[email protected]
